Thomas A. Abrams, Senior Physician and Assistant Medical Professor at Harvard Medical School provides results about the APACT
Study. APACT Study is a phase III trial of adjuvant nab-paclitaxel plus
gemcitabine versus gemcitabine for surgically resected pancreatic
adenocarcinoma.
Results of the APACT Study: Phase III Trial of Adjuvant Nab-Paclitaxel
